The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

Our objective was to evaluate the immunogenicity of branded and biosimilar infliximab by detecting changes in T-helper-9 (Th9) percentages induced by an in vitro stimulation test. Methods: Peripheral blood mononuclear cells collected from 55 consecutive rheumatoid arthritis (RA) outpatients (15 drug...

Full description

Bibliographic Details
Main Authors: Rossella Talotta, Angela Berzi, Andrea Doria, Alberto Batticciotto, Maria Chiara Ditto, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Daria Trabattoni
Format: Article
Language:English
Published: MDPI AG 2017-10-01
Series:International Journal of Molecular Sciences
Subjects:
biosimilars
Th9 lymphocytes
rheumatoid arthritis
infliximab
Online Access:https://www.mdpi.com/1422-0067/18/10/2127

Internet

https://www.mdpi.com/1422-0067/18/10/2127

Similar Items